Evaluation of the ischemia modified albumin levels in familial Mediterranean fever patients

Background Familial Mediterranean fever (FMF) is an autoimmune disease with periodic fever attacks recurring with mutations in the MEFV gene and chronic inflammation. The new molecule which is formed as a result of the chemical changes made by oxidative free radicals in the albumin molecule during ischemic events is called ischemia modified albumin (IMA). Aim The aim of this study is to evaluate the IMA levels as a predictor of the cardiovascular risk factor in FMF patients in the attack-free period and to evaluate the relationship between IMA and inflammation markers. Methods Forty FMF patients without any additional disease, non-smokers, and in their attacks-free period, 40 ankylosing spondylitis patients whose disease activity criteria is less than 4 from Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and 39 healthy adults were included in the cross-sectional analytical research. Results The value of IMA was statistically significantly higher in the AS group compared to the control group (p = 0.01). The positive correlations between IMA and ESR, LDL, total cholesterol, triglyceride, CRP, and fibrinogen were statistically significantly determined in FMF patients (respectively; r = 0.594; p < 0.001, r = 0.382; p = 0.015, r = 0.335; p = 0.034, r = 0.363; p = 0.021, r = 0.597; p < 0.001, r = 0.656; p < 0.001). The positive correlations between IMA and ESR, CRP were found in AS patients (respectively; r = 0.383; p = 0.015, r = 0.382; p = 0.015). Conclusion IMA can be used as a predictor similar to cardiovascular risk factors and it is a precious marker for inflammation. The use of IMA in these fields and the multi-centred and comparative studies about predictability of it may contribute to science.

Automated summary

This study aims to evaluate the levels of ischemia modified albumin (IMA) as a predictor of cardiovascular risk factors in Familial Mediterranean Fever (FMF) patients during the attack-free period and the relationship between IMA and inflammation markers. The results showed that IMA levels were significantly higher in FMF patients with positive correlations to ESR, LDL, total cholesterol, triglyceride, CRP, and fibrinogen. In AS patients, there were positive correlations between IMA and ESR, CRP. Conclusion: IMA can be used as a predictor for cardiovascular risk factors and is a valuable marker for inflammation.